MedTrace Logo

The Umeå High-Intensity Training Study

NCT03765385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2020-10-05

No results posted yet for this study

Summary

This randomized controlled trial will evaluate the effect of high-intensity training (HIT) in older sedentary people. Seventy older people, aged 65 and over, will be randomized to HIT or moderate-intensity continuous training (MICT). HIT sessions will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load. MICT (control group) sessions will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity. Both groups will be performed twice weekly for 12 weeks. The study will evaluate the effects on 1) Cardiovascular function, 2) Brain health, 3) Muscular function, 4) Psychological health, 5) Physical activity, 6) Metabolic health, and 7) Examine the feasibility (attendance, achieved intensity, adverse events) as well as the experiences of HIT. Most outcomes will be assessed at baseline, 3 months (directly after intervention period), and 9 months by blinded assessors.

Conditions

  • Aged

Interventions

OTHER

High-intensity training

Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.

OTHER

Moderate-intensity continuous training

Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.

Sponsors & Collaborators

  • Umeå University

    lead OTHER

Principal Investigators

  • Erik Rosendahl, Professor · Umeå University

  • Carl-Johan Boraxbekk, Professor · Umeå University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2020-02-05
Completion
2020-07-10

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03765385 on ClinicalTrials.gov